Cite

    Denise Yardley et al.. “Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.” Trials, vol. 17, no. 1, 2016, p. 1. http://access.bl.uk/ark:/81055/vdc_100080429382.0x00006f